Delta-Fly Pharma,Inc. [4598.T]
TOKYO, Apr 16 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) announced progress on its DFP single agent and Venetoclax (VEN) combination therapy trials.
In interim analysis of a phase three trial targeting relapsed/refractory acute myeloid leukemia patients, the drug showed higher efficacy rates compared to controls, though statistical significance was not achieved. Additionally, the combination therapy demonstrated promising results, achieving overall response rates of 28.84% in the first phase and 42.86% in the second phase.
Based on these findings, the company is preparing meetings with the FDA to advance conditional approval applications for the single agent and initiate global phase three trials for the combination therapy. Delta-Fly continues discussions with major pharmaceutical companies interested in licensing opportunities.
🟢 Confidence: High AI-translated content.